[1]何宗林,龙皆存,王家盛,等.肺癌筛查的现状与发展[J].医学信息,2024,37(13):169-173.[doi:10.3969/j.issn.1006-1959.2024.13.037]
　Current Status and Development of Lung Cancer Screening.Current Status and Development of Lung Cancer Screening[J].Journal of Medical Information,2024,37(13):169-173.[doi:10.3969/j.issn.1006-1959.2024.13.037]
点击复制

肺癌筛查的现状与发展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年13期
页码:
169-173
栏目:
综述
出版日期:
2024-07-01

文章信息/Info

Title:
Current Status and Development of Lung Cancer Screening
文章编号:
1006-1959（2024）13-0169-05
作者:
何宗林; 龙皆存; 王家盛; 等
（1.广西中医药大学研究生院，广西 南宁 530021；2.广西中医药大学第一附属医院/广西中医药大学第一临床医学院，广西 南宁 530021）
Author(s):
Current Status and Development of Lung Cancer Screening
(1.Graduate School of Guangxi University of Chinese Medicine,Nanning 530021,Guangxi,China;2.the First Affiliated Hospital of Guangxi University of Chinese Medicine/the First Clinical Medical Collegeof Guangxi University of Chinese Medicine,Nanning 53002
关键词:
肺癌; 早期筛查; 高危人群; 筛查技术; 成本效益; 筛查计划
Keywords:
Lung cancer; Early screening; High-risk population; Screening technology; Cost effectiveness; Screening plan
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2024.13.037
文献标志码:
A
摘要:
肺癌是全球死亡率排行首位的恶性肿瘤，由于病情发展快，治疗手段有限，现阶段仅在早期才有较好的预后。许多肺癌筛查实验中已经证明，通过筛查提高早期肺癌检出率是降低所有人群肺癌死亡率的有效措施，早诊断、诊断准是关键。完善筛查策略、合理划分界定高危人群标准是实现早诊早治需要解决的重要课题，需要进一步发掘肺癌筛查技术中影像学、生物标志物、人工智能等筛查方法在临床诊断与风险评估的潜力。本文回顾肺癌筛查历史的关键节点，综合分析肺癌筛查现状与发展的持续研究，以探讨肺癌筛查计划的可行性问题。
Abstract:
Lung cancer is the malignant tumor with the highest mortality rate in the world. Due to the rapid development of the disease and the limited treatment methods, it has a good prognosis only in the early stage. Many lung cancer screening experiments have proved that improving the detection rate of early lung cancer through screening is an effective measure to reduce the mortality rate of lung cancer in all populations. Early diagnosis and accurate diagnosis are the key. Improving screening strategies and rationally dividing and defining high-risk population standards are important issues to be solved in order to achieve early diagnosis and treatment. It is necessary to further explore the potential of imaging, biomarkers, artificial intelligence and other screening methods in lung cancer screening technology in clinical diagnosis and risk assessment. This article reviews the key nodes in the history of lung cancer screening, and comprehensively analyzes the continuous research on the status and development of lung cancer screening to explore the feasibility of lung cancer screening programs.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Public Health Agency of Canada,Statistics Canada,Canadian Cancer Society,et al.Release notice - Canadian Cancer Statistics 2019.Avis de publication - Statistiques canadiennes sur le cancer 2019[J].Health Promot Chronic Dis Prev Can,2019,39(8-9):255.[3]Sidorenkov G,Stadhouders R,Jacobs C,et al.Multi-source data approach for personalized outcome prediction in lung cancer screening:update from the NELSON trial[J].Eur J Epidemiol,2023,38(4):445-454.[4]Henschke CI,Yip R,Shaham D,et al.The Regimen of Computed Tomography Screening for Lung Cancer:Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program[J].J Thorac Imaging,2021,36(1):6-23.[5]De Koning HJ,van der Aalst CM,de Jong PA,et al.Reduced lung-cancer mortality with volume CT screening in a randomized trial[J].N Engl J Med,2020,382:503-513.[6]Pastorino U,Silva M,Sestini S,et al.Prolonged lung cancer screening reduced 10-year mortality in the MILD trial:new confirmation of lung cancer screening efficacy[J].Ann Oncol,2019,30(10):1672.[7]Li N,Tan F,Chen W,et al.One-off low-dose CT for lung cancer screening in China:a multicentre,population-based,prospective cohort study[J].Lancet Respir Med,2022,10(4):378-391.[8]Ettinger DS,Wood DE,Aisner DL,et al.Non-Small Cell Lung Cancer,Version 3.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(5):497-530.[9]梁文华,黎才琛,何建行.肺癌早筛早诊的精准化探索[J].中国肿瘤临床,2021,48(10):506-510.[10]Li C,Liang H,Zhong N,et al.Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography:A Population Level Analysis[J].Thorac Oncol,2019,14(4):e82-e84.[11]中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2022版)[J].中华肿瘤杂志,2022,44(6):457-490.[12]Koo HJ,Choi CM,Park S,et al.Chest radiography surveillance for lung cancer:Results from a National Health Insurance database in South Korea[J].Lung Cancer,2019,128:120-126.[13]屠娜娜.低剂量CT扫描与普通剂量扫描诊断早期肺癌的效果比较[J].医学信息,2021,34(9):112-114,118.[14]Mazzone PJ,Silvestri GA,Souter LH,et al.Screening for Lung Cancer:CHEST Guideline and Expert Panel Report[J].Chest,2021,160(5):e427-e494.[15]Bartlett EC,Silva M,Callister ME,et al.False-Negative Results in Lung Cancer Screening-Evidence and Controversies[J].J Thorac Oncol,2021,16(6):912-921.[16]Lu H,Mu W,Balagurunathan Y,et al.Multi-window CT based radiomic signatures in differentiating indolent versus aggressive lung cancers in the National Lung Screening Trial:a retrospective study[J].Cancer Imaging,2019,19(1):45.[17]Wang Y,Wu B,Zhang N,et al.Research progress of computer aided diagnosis system for pulmonary nodules in CT images[J].J Xray Sci Technol,2020,28(1):1-16.[18]Ardila D,Kiraly AP,Bharadwaj S,et al.End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography[J].Nat Med,2019,25(6):954-961.[19]Liu J,Yuan S,Wang L,et al.Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer:A Systematic Review and Meta-Analysis[J].Biomed Res Int,2019,2019:8534761.[20]Machado Medeiros T,Altmayer S,Watte G,et al.18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer:a systematic review and meta-analysis[J].Eur Radiol,2020,30(7):3641-3649.[21]Ohno Y,Ozawa Y,Koyama H,et al.State of the Art MR Imaging for Lung Cancer TNM Stage Evaluation[J].Cancers (Basel),2023,15(3):950.[22]Zhu J,Li W,Zhou J,et al.The diagnostic value of narrow-band imaging for early and invasive lung cancer:a meta-analysis[J].Clinics (Sao Paulo),2017,72(7):438-448.[23]Bae S,Lim S,Ahn JJ,et al.Diagnosing peripheral lung lesions using endobronchial ultrasonography with guide sheath:A prospective registry study to assess the effect of virtual bronchoscopic navigation using a computed tomography workstation[J].Medicine (Baltimore),2020,99(17):e19870.[24]Haince JF,Joubert P,Bach H,et al.Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer:From the Genome to the Metabolome[J].Int J Mol Sci,2022,23(3):1215.[25]Benbassat J.Duration of lead time in screening for lung cancer[J].BMC Pulm Med,2021,21(1):4.[26]Lemieux ME,Reveles XT,Rebeles J,et al.Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning[J].Respir Res,2023,24(1):23.[27]Yadav S,Kashaninejad N,Masud MK,et al.Autoantibodies as diagnostic and prognostic cancer biomarker:Detection techniques and approaches[J].Biosens Bioelectron,2019,139:111315.[28]Sullivan FM,Mair FS,Anderson W,et al.Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging[J].Eur Respir J,2021,57(1):2000670.[29]Massion PP,Healey GF,Peek LJ,et al.Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer[J].J Thorac Oncol,2017,12(3):578-584.[30]Schlander M,Richardson J.QALYs In Health Resource Usage Decisions[J].Health Aff (Millwood),2022,41(4):609-610.[31]Criss SD,de Koning HJ,Plevritis SK,et al.Cost-Effectiveness Analysis of Lung Cancer Screening in the United States[J].Ann Intern Med,2020,172(10):706-707.[32]Yang S,Liu T,Liang G.The benefits of smoking cessation on survival in cancer patients by integrative analysis of multi-omics data[J].Mol Oncol,2020,14(9):2069-2080.[33]Cressman S,Peacock SJ,Tammem?覿gi MC,et al.The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency[J].J Thorac Oncol,2017,12(8):1210-1222.

相似文献/References:

[1]尤 静.肺癌患者外周血CEA、NSE、CYFRA21-1联合检测的意义[J].医学信息,2018,31(06):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
　YOU Jing.Clinical Significance of Combined Detection of CEA,NSE,CYFRA21-1 in Peripheral Blood of Patients with Lung Cancer[J].Journal of Medical Information,2018,31(13):149.[doi:10.3969/j.issn.1006-1959.2018.06.052]
[2]戴 芳,曹晓美,王莉娜.肺癌患者疾病不确定感的影响因素与干预措施研究现状[J].医学信息,2018,31(08):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
　DAI Fang,CAO Xiao-mei,WANG Li-na.Research Status on Influencing Factors and Intervention Measures of Disease Uncertainty in Patients with Lung Cancer[J].Journal of Medical Information,2018,31(13):35.[doi:10.3969/j.issn.1006-1959.2018.08.012]
[3]邢益辉,刘 曼,厉玛倩倩,等.快速康复对肺癌手术患者并发症发生及生活质量的影响研究[J].医学信息,2018,31(16):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
　XING Yi-hui,LIU Man,LIMA Qian-qian,et al.Effect of Rapid Rehabilitation on Complications and Quality of Life in Patients with Lung Cancer Surgery[J].Journal of Medical Information,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.16.054]
[4]朱晓晓,张 顺,蔡 挺.镍暴露相关的肺癌发生分子机制研究[J].医学信息,2018,31(17):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
　ZHU Xiao-xiao,ZHANG Shun,CAI Ting.Molecular Mechanism of Lung Cancer Related to Nickel Exposure[J].Journal of Medical Information,2018,31(13):4.[doi:10.3969/j.issn.1006-1959.2018.17.002]
[5]付云杰.肺癌患者血浆D-二聚体、NSE及CYFRA21-1联合检测的临床价值[J].医学信息,2018,31(23):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
　FU Yun-jie.Clinical Value of the Plasma D-dimer and Serum NSE,CYFRA21-1 Combined Detection in the Diagnosis of Lung Cancer[J].Journal of Medical Information,2018,31(13):161.[doi:10.3969/j.issn.1006-1959.2018.23.047]
[6]覃柳麻,何慧敏.2014~2016年广西肿瘤医院肺癌患者流行病学及病理分布特征分析[J].医学信息,2019,32(05):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
　QIN Liu-ma,HE Hui-min.Epidemiological and Pathological Distribution Characteristics of Lung Cancer Patients in Guangxi Cancer Hospital from 2014 to 2016[J].Journal of Medical Information,2019,32(13):67.[doi:10.3969/j.issn.1006-1959.2019.05.021]
[7]魏优蕾,郭晓彤.肺癌患者血浆检测肿瘤标志物的分析方法及展望[J].医学信息,2019,32(07):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
　WEI You-lei,GUO Xiao-Tong.Analytical Methods and Prospects of Plasma Detection of Tumor Markers in Patients with Lung Cancer[J].Journal of Medical Information,2019,32(13):39.[doi:10.3969/j.issn.1006-1959.2019.07.014]
[8]杨寿林,宋庆志,吴路发,等.肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析[J].医学信息,2019,32(07):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
　YANG Shou-lin,SONG Qing-zhi,WU Lu-fa,et al.Efficacy Analysis of Tumor Markers and Coagulation Parameters in the Diagnosis of Lung Cancer[J].Journal of Medical Information,2019,32(13):168.[doi:10.3969/j.issn.1006-1959.2019.07.053]
[9]郭 磊,王小文,向小勇.中性粒细胞与淋巴细胞比值与肺癌预后关系研究[J].医学信息,2019,32(09):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
　GUO Lei,WANG Xiao-wen,XIANG Xiao-yong.Relationship between Neutrophil-lymphocyte Ratio and Prognosis of Lung Cancer[J].Journal of Medical Information,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
[10]王 猛.循环肿瘤细胞在肺癌诊疗中的临床研究进展[J].医学信息,2019,32(15):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]
　WANG Meng.Progress in Clinical Research of Circulating Tumor Cells in the Diagnosis and Treatment of Lung Cancer[J].Journal of Medical Information,2019,32(13):58.[doi:10.3969/j.issn.1006-1959.2019.15.019]

更新日期/Last Update: 1900-01-01